dc.contributor.author
Gollrad, Johannes
dc.contributor.author
Rabsahl, Christopher
dc.contributor.author
Riechardt, Aline-Isabel
dc.contributor.author
Heufelder, Jens
dc.contributor.author
Stroux, Andrea
dc.contributor.author
Goerling, Ute
dc.contributor.author
Joussen, Antonia
dc.contributor.author
Budach, Volker
dc.contributor.author
Boehmer, Dirk
dc.date.accessioned
2023-03-07T16:08:15Z
dc.date.available
2023-03-07T16:08:15Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/38236
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-37954
dc.description.abstract
Background: Proton beam therapy is a well-established treatment option for patients with uveal melanoma (UM). The treatment procedure, in general, includes placing radiopaque clips to ensure exact eye-positioning during radiotherapy, followed by the delivery of proton irradiation. The short-term burden associated with proton therapy in patients with UM has rarely been addressed. In this prospective study, we investigated the physiological and psychological aspects of proton therapy that might affect the well-being of patients during the different stages of treatment.
Methods: During the treatment procedure, we conducted longitudinal assessments of the Quality of life (QOL), organ-specific symptoms, and psychological aspects in patients with UM with three questionnaires (EORTC QLQ-C30, EORTC QLQ-OPT30, and GAD-7). Patients completed questionnaires before clip surgery (T0), before proton therapy (T1), after completing treatment (T2), and three months after treatment completion (T3). We also collected data on tumor characteristics and socio-demographics to identify potential risk factors associated with high treatment burdens.
Results: We prospectively included 131 consecutive patients. Questionnaire data showed a significant, temporary decline in global QOL and an increase in eye-related symptoms, as a result of the clip surgery (T0-T1). After treatment completion (T2), global QOL improved gradually, and none of the eye-related symptoms significantly deteriorated over the course of proton therapy. The global QOL returned to baseline levels three months after treatment (T3). We identified baseline anxiety as an independent risk factor for experiencing an acute treatment-related burden. Furthermore, we found interactions between GAD7 and patient sex showing that anxiety had a more pronounced effect on QOL outcome in female patients.
Conclusion: The short-term treatment-related burden of ocular proton therapy appeared to be largely associated with the preceding clip surgery, rather than the irradiation procedure. We found that anxiety was strongly associated with experiencing QOL issues during the treatment procedure. Our findings could contribute to the development of future strategies for improving the treatment process and psycho-oncologic patient care.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Uveal melanoma
en
dc.subject
Proton therapy
en
dc.subject
Quality of life
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Quality of life and treatment-related burden during ocular proton therapy: a prospective trial of 131 patients with uveal melanoma
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
174
dcterms.bibliographicCitation.doi
10.1186/s13014-021-01902-6
dcterms.bibliographicCitation.journaltitle
Radiation Oncology
dcterms.bibliographicCitation.originalpublishername
Springer Nature
dcterms.bibliographicCitation.volume
16
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
Springer Nature DEAL
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
34496895
dcterms.isPartOf.eissn
1748-717X